These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 1614054

  • 21. The compositional abnormalities of lipoproteins in diabetic renal failure.
    Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P.
    Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487
    [Abstract] [Full Text] [Related]

  • 22. Recent advances in factors that alter lipid metabolism in chronic renal failure.
    Drüeke T, Lacour B, Roullet JB, Funck-Brentano JL.
    Kidney Int Suppl; 1983 Dec; 16():S134-8. PubMed ID: 6588243
    [Abstract] [Full Text] [Related]

  • 23. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients.
    Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H.
    J Am Soc Nephrol; 1998 Jul; 9(7):1277-84. PubMed ID: 9644639
    [Abstract] [Full Text] [Related]

  • 24. [Hyperlipidemia in uremic patients in dialysis].
    Docci D, Bilancioni R, Turci F, Baldrati L.
    Quad Sclavo Diagn; 1985 Dec; 21(4):424-9. PubMed ID: 3837917
    [Abstract] [Full Text] [Related]

  • 25. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI, Schreier L, Elbert A, Berg G, Beresan H, López G, Wikinski R.
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [Abstract] [Full Text] [Related]

  • 26. Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients.
    Barbagallo CM, Noto D, Cefalù AB, Ganci A, Giammarresi C, Panno D, Cusumano G, Greco M, Di Gaudio F, Averna MR.
    Hemodial Int; 2015 Jul; 19(3):360-7. PubMed ID: 25495659
    [Abstract] [Full Text] [Related]

  • 27. The uremic dyslipidemia: a cross-sectional and longitudinal study.
    Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N.
    Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
    [Abstract] [Full Text] [Related]

  • 28. Effect of simvastatin on the lipid profile of hemodialysis patients.
    Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A, Kimura K, Takahashi T, Kishino M, Tone Y, Otani H, Ogawa A, Maeda T, Yukawa S.
    Kidney Int Suppl; 1999 Jul; 71():S219-21. PubMed ID: 10412781
    [Abstract] [Full Text] [Related]

  • 29. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD, Balagtas CC, Rowan JP, Black DM.
    Atherosclerosis; 1996 Nov 15; 127(1):113-22. PubMed ID: 9006811
    [Abstract] [Full Text] [Related]

  • 30. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P, Heinonen T, Shurzinske L, Black DM.
    Atherosclerosis; 1997 Aug 15; 133(1):123-33. PubMed ID: 9258416
    [Abstract] [Full Text] [Related]

  • 31. [Changes in HDL-cholesterol, subfractions HDL2 and HDL3 and apo-A, apo-A1 and apo-B lipoproteins in patients with chronic renal failure subjected to maintenance hemodialysis].
    Scarazatti E, Garavaglia G.
    Boll Soc Ital Biol Sper; 1985 Jan 30; 61(1):15-21. PubMed ID: 3977994
    [Abstract] [Full Text] [Related]

  • 32. Lipoprotein abnormalities in patients with secondary renal amyloidosis.
    Cengiz K, Bakan A, Yilmaz H.
    Int Urol Nephrol; 2001 Jan 30; 32(4):615-9. PubMed ID: 11989551
    [Abstract] [Full Text] [Related]

  • 33. Changes in the composition of plasma lipoproteins in the chronic uremic rat.
    Barry LE, Tan MH.
    Atherosclerosis; 1990 Dec 30; 85(2-3):139-50. PubMed ID: 2102077
    [Abstract] [Full Text] [Related]

  • 34. Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients.
    Alsayed N, Rebourcet R.
    Clin Chem; 1991 Mar 30; 37(3):387-93. PubMed ID: 2004445
    [Abstract] [Full Text] [Related]

  • 35. Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly.
    Räihä I, Marniemi J, Puukka P, Toikka T, Ehnholm C, Sourander L.
    Arterioscler Thromb Vasc Biol; 1997 Jul 30; 17(7):1224-32. PubMed ID: 9261250
    [Abstract] [Full Text] [Related]

  • 36. Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease.
    Tsumura M, Kinouchi T, Ono S, Nakajima T, Komoda T.
    Clin Chim Acta; 2001 Dec 30; 314(1-2):27-37. PubMed ID: 11718676
    [Abstract] [Full Text] [Related]

  • 37. Hyperlipidemia of chronic renal failure.
    Kaysen GA.
    Blood Purif; 1994 Dec 30; 12(1):60-7. PubMed ID: 7986478
    [Abstract] [Full Text] [Related]

  • 38. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.
    Pelegrí A, Romero R, Sentí M, Nogués X, Pedro-Botet J, Rubiés-Prat J.
    Nephrol Dial Transplant; 1992 Dec 30; 7(7):623-6. PubMed ID: 1323073
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis.
    Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T, Yamakido M.
    Nephron; 1997 Dec 30; 76(1):7-14. PubMed ID: 9171293
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.